Dare Bioscience (DARE) Return on Capital Employed (2017 - 2026)
Dare Bioscience's (DARE) quarterly Return on Capital Employed came in at 170.99% in Q4 2025, down 170066.0% YoY from N/an in Q4 2024, and up 93.66% on a QoQ basis from 2697.31% in Q3 2025.
Dare Bioscience (DARE) Return on Capital Employed (2017 - 2026) Analysis & Trends
Dare Bioscience (DARE) has 9 years of Return on Capital Employed data on file, last reported at 170.99% in Q4 2025.
- Quarterly Return on Capital Employed fell 170066.0% year-over-year to 170.99% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 170.99% (down 170066.0% YoY) and the FY2025 annual result came in at 376.23%, up 2945799.0% from the prior year.
- Return on Capital Employed improved to 170.99% in Q4 2025, from 2697.31% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 4949.38% in Q1 2024 to a low of 2697.31% in Q3 2025.
- A 5-year average of 97.42% and a median of 186.88% in 2022 frame the typical range for Return on Capital Employed.
- The widest YoY moves for Return on Capital Employed: up 1483669 bps in 2021, down 5050364 bps in 2021.
- Tracing DARE's Return on Capital Employed over 5 years: stood at 107.76% in 2021, then plunged by 88 bps to 202.78% in 2022, then sank by 468 bps to 1151.17% in 2023, then soared by 233 bps to 1529.68% in 2024, then slumped by 111 bps to 170.99% in 2025.
- The last three Return on Capital Employed figures came in at 170.99% (Q4 2025), 2697.31% (Q3 2025), and 540.0% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Dare Bioscience | 11.91 Mn | -705,728.22 | -132,343.00 | -113.71% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -113.71% |
| Dec 31, 2025 | -170.99% |
| Sep 30, 2025 | -2,697.31% |
| Jun 30, 2025 | 540.00% |
| Mar 31, 2025 | 2,658.11% |
| Dec 31, 2024 | 1,529.68% |
| Sep 30, 2024 | -302.66% |
| Jun 30, 2024 | -724.55% |
| Mar 31, 2024 | 4,949.38% |
| Dec 31, 2023 | -1,151.17% |
| Sep 30, 2023 | 1,899.74% |
| Jun 30, 2023 | -1,951.69% |
| Mar 31, 2023 | -245.86% |
| Dec 31, 2022 | -202.78% |
| Sep 30, 2022 | -88.06% |
| Jun 30, 2022 | -89.56% |
| Mar 31, 2022 | -110.17% |
| Dec 31, 2021 | -107.76% |
| Sep 30, 2021 | -238.63% |
| Jun 30, 2021 | -493.27% |